

03-11-02 70482 . 080402 PCT \$


JC07 Rec'd PCT/PTO 0 8 . MAR 2002

FORM PTO-1106 DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE (Rev. 1-98)		ATTORNEY'S DOCKET NO. FBRCC:011US
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371		U.S. APPLICATION NO. (if known, see 37 CFR 1.5) N/A 10/070982
INTERNATIONAL APPLICATION NO. PCT/AU00/01083	INTERNATIONAL FILING DATE 11 September 2000	PRIORITY DATE CLAIMED 9 September 1999
TITLE OF INVENTION Dendritic Cell Membrane Protein FIRE		
APPLICANT(S) FOR DO/EO/US Caminschi, Irina; Vandenabeele, Stephane Alain; Wright, Mark Dexter; Shortman, Kenneth Douglas		
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:		
<p><input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.</p> <p><input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.</p> <p>3. <input type="checkbox"/> This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).</p> <p>4. <input checked="" type="checkbox"/> A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.</p> <p>5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2)).</p> <p style="padding-left: 20px;">a. <input checked="" type="checkbox"/> is transmitted herewith (required only if not transmitted by the International bureau).</p> <p style="padding-left: 20px;">b. <input type="checkbox"/> has been transmitted by the International Bureau.</p> <p style="padding-left: 20px;">c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US)</p> <p>6. <input type="checkbox"/> A translation of the International Application into English (35 U.S.C. 371(c)(2)).</p> <p>7. <input type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))</p> <p style="padding-left: 20px;">a. <input type="checkbox"/> are transmitted herewith (required only if not transmitted by the International Bureau)</p> <p style="padding-left: 20px;">b. <input type="checkbox"/> have been transmitted by the International Bureau.</p> <p style="padding-left: 20px;">c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired.</p> <p style="padding-left: 20px;">d. <input type="checkbox"/> have not been made and will not be made.</p> <p>8. <input type="checkbox"/> A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).</p> <p>9. <input type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).</p> <p>10. <input type="checkbox"/> A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).</p>		
Items 11 to 16 below concern document(s) or information included:		
11. <input type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98.		
12. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.		
13. <input checked="" type="checkbox"/> A FIRST preliminary amendment.		
<input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment.		
14. <input type="checkbox"/> A substitute specification.		
15. <input type="checkbox"/> A change of power of attorney and/or address letter.		
16. <input type="checkbox"/> Other items or information: PCT Publication A1 OF WO 01/18047 comprising the application papers as filed; Amended pages under Article 34 (pages 11, 12 and 12/1; PCT request of September 11, 2000; PCT Publication A1 of WO 01/18047 comprising the international search report (ISR), IPER of October 5, 2001.		

O I P E
MAR 10 8 2002
PATENT & TRADEMARK OFFICE

EXPRESS MAIL MAILING LABEL
EXPRESS MAIL NO.: EL79453515US
DATE OF DEPOSIT: MARCH 8, 2002

JC13 Rec'd PCT/PTC 08 MAR 2002

U.S. APPLICATION NO. (If known use 37 CFR 1.5) 10/070982		INTERNATIONAL APPLICATION NO. PCT/AU00/01083	ATTORNEY'S DOCKET NUMBER FBR0011US
17 <input type="checkbox"/> The following fees are submitted: Basic National Fee (37 CFR 1.492(a)(1)-(5)): Neither international preliminary examination fee (37 CFR 1.482) Nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO And International Search Report not prepared by the EPO or JPO.....\$1,000.00 International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO \$ 860.00 International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO \$ 710.00 International preliminary examination fee (37 CFR 1.482) paid to USPTO But all claims did not satisfy provisions of PCT Article 33(1)-(4) \$ 690.00 International preliminary examination fee (37 CFR 1.482) paid to USPTO And all claims satisfied provisions of PCT Article 33(2)-(4) \$ 100.00			CALCULATIONS PTO USE ONLY
ENTER APPROPRIATE BASIC FEE AMOUNT = \$1,000.00			
Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input checked="" type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(e)).			\$ 130.00
Claims	Number Filed	Number Extra	Rate
Total Claims	1- 20 =		x \$ 18.00 \$
Independent Claims	1- 2 =		x \$ 80.00 \$
Multiple dependent claim(s) (if applicable)			+ \$270.00 \$
TOTAL OF ABOVE CALCULATIONS			= \$.00
Reduction by 1/2 for filing by small entity, if applicable. Applicant is entitled to small entity status pursuant to 37 CFR 1.27.			\$-0-.00
SUBTOTAL			= \$ 1130.00
Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)).			\$-0-.00
TOTAL NATIONAL FEE			= \$ 1130.00
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property)			+ \$-0-.00
TOTAL FEES ENCLOSED			= \$ 1130.00
			Amount to be refunded: \$.00
			Charged: \$.00
a. <input checked="" type="checkbox"/> A check in the amount of \$1130.00 to cover the above fees is enclosed. b. <input type="checkbox"/> Please charge Deposit Account No. 50-1212/_____ in the amount of \$_____ to cover the above fees. A duplicate copy of this sheet is enclosed. c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 50-1212/10011874/SLH. A duplicate copy of this sheet is enclosed.			
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.			
SEND ALL CORRESPONDENCE TO: Thomas M. Boyce, ESQ. FULBRIGHT & JAWORSKI L.L.P. 600 Congress Avenue, Suite 2400 Austin, Texas 78701 512.474.5201			
SIGNATURE  Steven L. Highlander NAME 37,642 REGISTRATION NUMBER			

18 DEC 2002
#5

CERTIFICATE OF MAILING 37 C.F.R. 1.8	
I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to. U.S. Patent and Trademark Office, Box Sequence, P.O. Box 2327, Arlington, VA 22202, on the date below:	
December 13, 2002	<i>Michael Kravtzenek</i>
Date	Michael Kravtzenek

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Irina Caminschi, Stephane Alain
Vandenabeele, Mark Dexter Wright and
Kenneth Douglas Shortman

Group Art Unit: Unassigned

Examiner: Unassigned

Serial No.: 10/070,982

Atty. Dkt. No.: FBRC:011US/TMB

Filed: March 8, 2002

For: DENDRITIC CELL MEMBRANE
PROTEIN FIRE

STATEMENT AS REQUIRED UNDER 37 C.F.R. § 1.825(a) AND (b)
AND STATEMENT AS REQUIRED UNDER 37 C.F.R. § 1.821(g)

U.S. Patent and Trademark Office
Box Sequence, P.O. Box 2327
Arlington, VA 22202

Commissioner:

Submitted herewith is a substitute computer readable form and a substitute paper copy of the sequence listing of those sequences in the captioned patent application, wherein minor errors have been corrected. The substitute computer readable form of the sequence listing is the same as the substitute paper copy of the sequence listing. The sequence information provided in the Specification is also the same as the sequence listing of the enclosed substitute computer readable and paper forms of the sequence listing.

In accordance with 37 C.F.R. § 1.821(g), it is herewith represented that no new matter is included with this submission.

Respectfully submitted,

Michael R. Krawesnek 51,898

for

Michael R. Krawesnek

Thomas M. Boyce

Reg. No. 43,508

Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P.
600 Congress Avenue, Suite 2400
Austin, Texas 78701
(512) 536-3043

Date: December 13, 2002

PTO/PCT Re. 00 AUG 2002

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:
Irina Caminschi, et al.

Serial No.: 10/070,982

Filed: March 8, 2002

For: DENDRITIC CELL MEMBRANE
PROTEIN FIRE

Group Art Unit: Unknown

Examiner: Unknown

Atty. Dkt. No.: FBRC:011US

EXPRESS MAIL MAILING LABEL	
NUMBER	EL 839265725 US
DATE OF DEPOSIT	August 9, 2002

STATEMENT AS REQUIRED UNDER 37 C.F.R. § 1.825(a) AND (b)
AND STATEMENT AS REQUIRED UNDER 37 C.F.R. § 1.821(g)

BOX PCT


Commissioner for Patents
Washington, D.C. 20231

Commissioner:

Submitted herewith is a substitute computer readable form and a substitute paper copy of the sequence listing of those sequences in the captioned patent application, wherein minor errors have been corrected. The substitute computer readable form of the sequence listing is the same as the substitute paper copy of the sequence listing. The sequence information provided in the Specification is also the same as the sequence listing of the enclosed substitute computer readable and paper forms of the sequence listing.

In accordance with 37 C.F.R. § 1.821(g), it is herewith represented that no new matter is included with this submission.

Respectfully submitted,



Thomas M. Boyce
Reg. No. 43,508
Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P.
600 Congress Avenue, Suite 2400
Austin, Texas 78701
(512) 474-5201

Date: August 9, 2002